Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 7/20 | 0.73 |
| ▸ | LAP3 | P28838 | 1/20 | 0.73 |
| ▸ | PPARG | P37231 | 3/20 | 0.58 |
| ▸ | PPARA | Q07869 | 3/20 | 0.58 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.57 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.57 |
| ▸ | MAOB | P27338 | 2/20 | 0.55 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.55 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.55 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.54 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.54 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.54 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.52 |
| ▸ | PPARD | Q03181 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6561218 | 1.00 | LTA4H (0.73) | LTA4HLAP3PPARGPPARAFFAR1 | |
| SCHEMBL8413771 | 1.00 | LTA4H (0.73) | LTA4HLAP3PPARGPPARAFFAR1 | |
| Hydrochloric Acid SCHEMBL6271718 | 0.99 | LTA4H (0.71) | LTA4HLAP3PPARGPPARAFFAR1 | |
| Hydrochloric Acid SCHEMBL10922580 | 0.99 | LTA4H (0.71) | LTA4HLAP3PPARGPPARAFFAR1 | |
| SCHEMBL17738622 | 0.93 | LTA4H (0.64) | LTA4HLAP3PPARGPPARAFFAR1 | |
| SCHEMBL18025356 | 0.93 | LTA4H (0.64) | LTA4HLAP3PPARGPPARAFFAR1 | |
| SCHEMBL16607620 | 0.93 | LTA4H (0.67) | LTA4HLAP3PPARGPPARAFFAR1 | |
| SCHEMBL6713179 | 0.90 | LMNA (0.64) | LTA4HLAP3PPARGPPARAFFAR1 | |
| SCHEMBL9731697 | 0.90 | LTA4H (0.61) | LTA4HLAP3PPARGPPARAMAOB | |
| SCHEMBL9731692 | 0.90 | LTA4H (0.61) | LTA4HLAP3PPARGPPARAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022191338-A1 | LEVODOPA-PRODRUGS AND CARBIDOPA-PRODRUGS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2022-09-15 | — | — | WO | disclosed |
| EP-1697400-B1 | BIPHENYL-SUBSTITUTED ANTIBACTERIAL MACROCYCLES | AICURIS GMBH & CO KG (DE) | 2011-05-25 | — | — | EP | disclosed |
| US-20040062773-A1 | Compositions for the delivery of antigens | EMISPHERE TECHNOLOGIES INC. | 2004-04-01 | — | — | US | disclosed |
| EP-0784469-B1 | COMPOSITIONS FOR THE DELIVERY OF ANTIGENS | EMISPHERE TECH INC (US) | 2004-03-24 | — | — | EP | disclosed |
| US-6610329-B2 | Using acylated amino acid as carrier | EMISPHERE TECHNOLOGIES INC. | 2003-08-26 | — | — | US | disclosed |
| US-20020001591-A1 | Compositions for the delivery of antigens | EMISPHERE TECHNOLOGIES, INC. | 2002-01-03 | — | — | US | disclosed |
| US-5958457-A | MIXTURES OF ANTIGENS WITH ADJUVANTS AND ACYLATED AMINO ACIDS OR SALTS, POLYMERS OR SULFONATED AMINO ACIDS | EMISPHERE TECHNOLOGIES, INC. (US) | 1999-09-28 | — | — | US | disclosed |
| EP-0784469-A4 | COMPOSITIONS FOR THE DELIVERY OF ANTIGENS | EMISPHERE TECH INC (US) | 1999-03-24 | — | — | EP | disclosed |
| EP-0784469-A1 | COMPOSITIONS FOR THE DELIVERY OF ANTIGENS | Emisphere Technologies, Inc. (US) | 1997-07-23 | — | — | EP | disclosed |
| WO-1996012474-A1 | COMPOSITIONS FOR THE DELIVERY OF ANTIGENS | EMISPHERE TECHNOLOGIES, INC. (US) | 1996-05-02 | — | — | WO | disclosed |
| EP-0226158-B1 | PEPTIDES CORRELATED TO LYSOZYME | S P A SOCIETA' PRODOTTI ANTIBIOTICI S.p.a. (IT) | 1992-06-10 | — | — | EP | disclosed |
| US-4784988-A | OLIGO AND POLYPEPTIDES, ANALGESICS, VIRICIDES | SPA SOCIETA' PRODOTTI ANTIBIOTICI S.P.A. (IT) | 1988-11-15 | — | — | US | disclosed |
| EP-0226158-A2 | Peptides correlated to lysozyme | S P A SOCIETA' PRODOTTI ANTIBIOTICI S.p.a. (IT) | 1987-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020001591-A1 | Compositions for the delivery of antigens | CD47, CD74, LY96 | LTA4H 1415/4885LAP3 286/4885PPARG 2770/4885 |
| US-20040062773-A1 | Compositions for the delivery of antigens | CD47, CD74, LY96 | LTA4H 1415/4885LAP3 286/4885PPARG 2770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.